Insulet first launched its Omnipod 5 patch-pump for people with Type 1 diabetes in 2022. Now, the device is also indicated for people with Type 2 diabetes ages 18 years and older.

The insulin pump market is projected to reach $14bn in the same period, as per GlobalData analysis. Insulet also secured label expansion for Omnipod 5 device from the FDA allowing for its use in ...

ACTON, Mass., August 26, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today ...

ACTON, Mass., August 26, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...

Insulet Corporation PODD reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million. Total Omnipod revenue of $422 million marked a ...

Insulet continues to see adoption of its Omnipod 5 pump—the device that represents Insulet's entrance into hybrid closed-loop technology that makes life easier by automating insulin delivery, or ...

Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5 is now commercially available in Canada.

JOHOR BAHRU, Aug 14 (Bernama) -- United States-based medical device company Insulet Corporation’s new manufacturing facility in Johor Bahru will position the company strategically to stay ahead of the ...

Sales of Omnipod insulin pumps came in at $585.7 million for the fourth quarter, compared with analysts' estimates of $576 million. It expects Omnipod revenue growth in the range of 17per cent to ...